Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from INCY

Incyte is all set to release its fiscal first-quarter earnings later this month, and analysts project a high double-digit profit growth.

Barchart

Incyte Stock: Is INCY Outperforming the Health Care Sector?

Incyte has outperformed the health care sector over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart

Are Wall Street Analysts Bullish on Incyte Stock?

Incyte has continued to observe strong demand for Jakafi and Opzelura, leading to robust growth in sales, and analysts remain bullish on the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

What You Need to Know Ahead of Incyte's Earnings Release

Biopharma major Incyte is expected to announce its fourth-quarter results later this month and analysts expect a significant double-digit growth in earnings.

Barchart

Is Incyte Stock Outperforming the Dow?

Incyte has outperformed the Dow recently, and analysts remain moderately optimistic about the stock’s prospects.

Barchart

What Are Wall Street Analysts' Target Price for Incyte Stock?

Despite Incyte Corporation’s underperformance relative to the broader S&P 500 Index, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

What to Expect From Incyte's Next Quarterly Earnings Report

Incyte will release its third-quarter earnings later this month, and analysts anticipate a double-digit profit growth.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Is Incyte Stock Underperforming the Nasdaq?

Despite Incyte’s underperformance relative to the Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Incyte Stock: Is Wall Street Bullish or Bearish?

While Incyte has underperformed the broader market over the past year, Wall Street analysts remain moderately bullish about the stock’s prospects.

Barchart

What to Expect From Incyte’s Q2 2024 Earnings Report

Incyte will release its second-quarter earnings later this month, and analysts anticipate a double-digit profit growth.

Barchart

3 Value Stocks With Strong Fundamentals to Buy Now

Value investing is highly favored as it focuses on purchasing undervalued stocks with solid fundamentals, providing the potential for high returns with lower risk and a disciplined, long-term approach. Therefore, it could be wise to invest in fundamentally sound, value stocks Expedia Group (EXPE), Incyte (INCY), and Albertsons Companies (ACI)…

StockNews.com

3 Biotech Gems Poised for April Breakthroughs

The biotechnology industry is expected to grow rapidly due to rising demand for personalized medicines, increased R&D spending, and the adoption of AI in the biopharma market. Hence, quality biotech stocks Incyte (INCY), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) could be poised for breakthroughs this month. Read more….

StockNews.com

4 A-Rated Biotech Stocks Sparking Investor Interest

The biotech industry is rapidly evolving thanks to the surging biopharma M&A activity and incorporation of new technological trends like AI and gene editing. Given this backdrop, quality biotech stocks Gilead Sciences (GILD), Equillium (EQ), Incyte Corporation (INCY), and Jazz Pharmaceuticals plc (JAZZ), rated A (Strong Buy) overall in our…

StockNews.com

Top 3 Biotech Stocks to Consider for March Profits

The biotech sector’s growth prospects look promising thanks to the growing use of cutting-edge technologies in healthcare and the rising popularity of personalized medicines. Therefore, it could be wise to buy fundamentally strong biotech stocks Shionogi (SGIOY), Alkermes (ALKS), and Incyte (INCY) for March profits. Read more.

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Elite 4 Biotech Stocks to Buy Now for Explosive Returns

With a wide range of applications across sectors, including health, agriculture, and industrial processing, rapid technological adoption, and government support, the biotech industry’s prospects appear promising. Thus, investors could consider buying biotech stocks Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Incyte (INCY), and Exelixis (EXEL) for substantial gains. Read on….

StockNews.com

3 Biotech Stock Sensations to Snatch up This Week

The future of the biotech industry appears promising, fueled by technology-driven advancements, increasing merger and acquisition maneuvers, and developing product pipelines. Given this backdrop, quality biotech stocks BioNTech SE (BNTX), Entrada Therapeutics (TRDA), and Incyte Corporation (INCY) could be wise to snatch up this week. Read on….

Barchart

2 Best Growth Stocks to Buy with $1,000 Right Now

Growth stocks are getting ready for a comeback year in 2024, and these two under-the-radar stocks have solid financials and significant upside potential.

StockNews.com

3 Food Maker Stock Buys for Year-End Success

The global food service industry is thriving, fueled by diverse culinary preferences and technological integration. Hence, fundamentally strong food maker stocks Danone (DANOY), Ingredion Incorporated (INGR), and Tate & Lyle (TATYY) might be solid investments for year-end gains. Read more….

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Top 4 Biotech Stock Buys for 2024 Gains

The biotech industry's dynamic growth, spurred by government backing and technological advances, addresses rising disease challenges and propels advancements in healthcare. Hence, fundamentally strong biotech stocks Gilead Sciences (GILD), Incyte Corporation (INCY), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) might be solid investments for upcoming year gains. Read more….

StockNews.com

Are These the Top 3 Biotech Stocks Set for Year-End Profits?

As the biotech industry experiences robust growth, driven by innovation, government initiatives, and global market expansion, let us delve into fundamentally solid biotech stocks Gilead Sciences (GILD), Exelixis (EXEL), and Incyte Corp (INCY) to evaluate their year-end profitability potential. Read more to find out….

StockNews.com

3 Biotech Stocks Bursting With Investment Potential

The biotech industry is well-positioned for robust growth thanks to the increasing demand for effective treatments for chronic diseases and the need to serve an aging population. To capitalize on the favorable industry trends, investing in quality biotech stocks Organogenesis Holdings (ORGO), Genmab A/S (GMAB), and Incyte (INCY) could be…

StockNews.com

3 Revolutionary Biotech Stocks Worth Investing In

The biotech industry's upward momentum is underpinned by the growth of personalized medicine, orphan drugs, innovative biotech tools, and robust government backing. Hence, revolutionary biotech stocks Equillium (EQ), Protalix BioTherapeutics (PLX), and Incyte Corporation (INCY) could make ideal additions to your portfolio at present. Read more….

StockNews.com

Exploring the Upside Potential of 3 Biotech Stocks

Given the breakthrough developments, government support, and rising need to treat chronic diseases, the biotech industry is well-positioned to grow steadily. So, it could be wise to invest in quality biotech stocks Alkermes (ALKS), Amgen (AMGN) and Incyte (INCY). Read on….

StockNews.com

Investors Keeping a Close Eye on These 3 Biotech Stocks

Growing adoption of AI technologies by biopharmaceutical companies and growing foothold of personalized medicine are expected to drive growth in the biotech market. Therefore, it could be wise to buy fundamentally strong biotech stocks Regeneron Pharmaceuticals (REGN), Corcept Therapeutics (CORT), and Incyte (INCY). Read more.

StockNews.com

3 Biotech Stocks to Buy under $20

The growing adoption of advanced technologies by biopharmaceutical companies and the growing demand for personalized medicines are expected to boost the biotech industry. Therefore, it could be wise to buy fundamentally strong biotech stocks MacroGenics (MGNX), Acorda Therapeutics (ACOR), and Shionogi & Co. (SGIOY), which are currently trading under $20.…

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.